<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36729344</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>134</EndPage><MedlinePgn>117-134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-022-01824-x</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is characterized by an aberrant immune response, leading to an extremely heterogeneous clinical presentation, potentially affecting different systems and organs. Despite the fact that SLE mortality has greatly decreased since the introduction of steroids, some forms of refractory/severe SLE still have the potential to result in permanent organ damage as well as increased mortality and morbidity. Furthermore, SLE patients with multiple comorbidities may face a clinical conundrum and have a bad prognosis. An improved prognosis for severe refractory SLE depends on prompt and appropriate treatment. Due to the scarcity of solid data from a well-characterized group of patients with refractory/severe SLE coming from randomized controlled studies, this review aims to shed light on this with real-world evidence from clinical research performed at our Unit, the University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) (Turin, Italy). In order to determine the key clinical and prognostic features, and therapeutic approaches for severe and/or refractory SLE, our experience will be described together with existing literature, primarily focused on dermatological, neuropsychiatric, and renal symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Roccatello</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy. dario.roccatello@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sciascia</LastName><ForeName>Savino</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rossi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fenoglio</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="Y">Rare Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36729344</ArticleId><ArticleId IdType="doi">10.1007/s40265-022-01824-x</ArticleId><ArticleId IdType="pii">10.1007/s40265-022-01824-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Liu H, Zhou Z, Zhao L, Fei Y, Chen H, et al. Management of severe refractory systemic lupus erythematosus: real-world experience and literature review. Clin Rev Allergy Immunol. 2021;60(1):17&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-020-08817-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl5):v69&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bela MM, Espinosa G, Cervera R. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus. 2021;30(1):134&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320965707</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Mosca M, R&#xed;os-Garc&#xe9;s R, Espinosa G, Trujillo H, Bada T, Praga M. Treatment for refractory lupus nephritis: rituximab vs triple target therapy. Autoimmun Rev. 2019;18(12): 102406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102406</ArticleId></ArticleIdList></Reference><Reference><Citation>Yo JH, Barbour TD, Nicholls K. Management of refractory lupus nephritis: challenges and solutions. Open Access Rheumatol. 2019;11:179&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S166303</ArticleId></ArticleIdList></Reference><Reference><Citation>Enriquez Merayo E, Sciascia S, Roccatello D, Cuadrado MJ. Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids? Expert Rev Clin Immunol. 2018;14(11):877&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2018.1527219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Mompean E, Radin M, Roccatello D, Cuadrado MJ. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig. 2017;37(6):519&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-017-0518-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Zhou H, Fang D, Yi P, Cao P, Liu J, et al. The global burden of heterogeneity of lupus erythematosus interventional trials. J Autoimmun. 2022;128: 102798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32(9):1107&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780320909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernder A, Richter JG, Fischer-Betz R, Winkler-Rohlfing B, Brinks R, Aringer M, Schneider M, Chehab G. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort. Lupus. 2021;30(3):431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320983445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanetti CB, Pedrosa T, Kupa LVK, Aikawa NE, Borba EF, Vendramini MBG, Silva CA, Pasoto SG, Bonfa E. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2&#x2013;3 mg/kg/day): 12-month prospective randomized controlled trial. Clin Rheumatol. 2021;40(7):2745&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05600-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrosa T, Kupa LVK, Pasoto SG, Aikawa NE, Borba EF, Duarte NJ, et al. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus. 2021;30(4):554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320985214</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Zahr N, Costedoat-Chalumeau N, Amoura Z. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev. 2011;10(11):674&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.04.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047&#x2013;54.</Citation></Reference><Reference><Citation>Islam R, Das S, Chattopadhyay S, Basu S. Neuropsychiatric lupus with posterior reversible encephalopathy syndrome: a rare presentation. BMJ Case Rep. 2021;14(6): e241494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-241494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Bertolaccini ML, Baldovino S, Roccatello D, Khamashta MA, Sanna G. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev. 2013;12(3):426&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2012.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Ni R, Liu H. Intestinal pseudo-obstruction in systemic lupus erythematosus: an analysis of nationwide inpatient sample. Clin Rheumatol. 2022. https://doi.org/10.1007/s10067-022-06283-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06283-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C, Elefante E, Arnaud L, Barreira SC, Bulina I, Cavagna L, et al. Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clin Exp Rheumatol. 2022;40 Suppl 134(5):93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/jrz47c</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, Han S. Bilateral ureteral calcification with left kidney hydronephrosis in systemic lupus erythematosus. Kidney Res Clin Pract. 2016;35(1):65&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.krcp.2016.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Cecchi I, Fenoglio R, De Marchi A, Besso L, et al. Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol. 2020;33(4):757&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-019-00698-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Yazdany J, Dall&#x2019;Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study. Ann Rheum Dis. 2019;78(7):1004&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3686-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Qian J, Li M, Zhang X, Wei W, Zuo X, et al. Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Ther Adv Chronic Dis. 2022;13:20406223221112530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221112528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Cuadrado MJ, Karim MY. Management of infection in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):377&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2013.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Camara I, Sciascia S, Simoes J, Pazzola G, Salas V, Karim Y, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol. 2014;32(1):41&#x2013;7.</Citation></Reference><Reference><Citation>Sciascia S, Fenoglio R, Roccatello D. Moving toward personalized approaches in the management of lupus nephritis. Expert Opin Biol Ther. 2021;21(12):1547&#x2013;50. https://doi.org/10.1080/14712598.2022.1998449 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2022.1998449</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Fenoglio R, Rossi D. A new challenge for lupus nephritis management: induction therapy without immunosuppressive maintenance regimen. Autoimmun Rev. 2021;20(7): 102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102844</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. NephrolDialTransplant. 2011;26:3987&#x2013;92.</Citation></Reference><Reference><Citation>Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.07.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribero S, Sciascia S, Borradori L, Lipsker D. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol. 2017;53(3):291&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8627-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes D, Ortega-Loayza AG. Adverse cutaneous reactions to chemotherapeutic drugs. Clin Dermatol. 2020;38(6):712&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2020.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara K, Hughes OB, Strowd LC. Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-related intertriginous and flexural exanthema, and drug-induced lupus. Clin Dermatol. 2020;38(6):641&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2020.06.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisis D, Bernier C, Chasset F, Arnaud L. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(11): 102393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Ramsey-Goldman R, Urowitz MB, Hanly JG, Gordon C, Petri MA, et al. Cancer risk in a large inception systemic lupus erythematosus cohort: effects of demographic characteristics, smoking, and medications. Arthritis Care Res (Hoboken). 2021;73(12):1789&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24425</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtiss P, Walker AM, Chong BF. A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus. Front Immunol. 2022;13: 866319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.866319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;3(3): CD007478.</Citation></Reference><Reference><Citation>Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11310780-000000000-00000</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarini AA, Kerl K, French LE, Tr&#xfc;eb RM. Control of widespread hypertrophic lupus erythematosus with T-cell-directed biologic efalizumab. Dermatology. 2010;220(3):249&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000277614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprow G, Dan J, Merola JF, Werth VP. Emerging therapies in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9: 968323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.968323</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators. Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, Illei G, Tummala R. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1): e000284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000284</ArticleId></ArticleIdList></Reference><Reference><Citation>Loncharich MF, Anderson CW. Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval. ACR Open Rheumatol. 2022;4(6):486&#x2013;91. https://doi.org/10.1002/acr2.11414 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: &#x201c;extra-criteria&#x201d; manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. https://doi.org/10.1038/nrdp.2017.103 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Rev Clin Immunol. 2022;18(3):245&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2040988</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter A, Licciardi-Fernandez MJ, Burmann SN, Paschos A, Michalowitz AL. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47(4):787&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.15044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolezalova P, Anton J, Avcin T, Beresford MW, Brogan PA, Constantin T, et al. The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology (Oxford). 2019;58(7):1188&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, et al. JAK115919 Study Team. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 2016;25(13):1420&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316640910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol. 2019;15(7):693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1608821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId></ArticleIdList></Reference><Reference><Citation>You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, Li H, Li M, Zeng X. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215455</ArticleId></ArticleIdList></Reference><Reference><Citation>Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;6: e001263.</Citation></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients wit active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall&#x2019;Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephr. 2018;13:1502&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01070118</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S, Naretto C, Alpa M, Fenoglio R, Ferro M, et al. A Prospective study on long-term clinical outcomes of patients with lupus nephritis treated with an intensified B-cell depletion protocol without maintenance therapy. Kidney In Rep. 2021;6(4):1081&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.01.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: a systematic review and network meta-analysis. Front Immunol. 2022;13: 859380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.859380</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualtierotti R, Borghi MO, Gerosa M, Schioppo T, Larghi P, Geginat J, Meroni PL. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. Clin Exp Rheumatol. 2018;36(4):643&#x2013;7.</Citation></Reference><Reference><Citation>Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41466</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9(3): e025687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-025687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League against rheumatism and European renal Association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des. 2008;14(13):1261&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161208799316401</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D, Sciascia S. A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome. Kidney Int. 2021;100(4):740&#x2013;42.</Citation></Reference><Reference><Citation>Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.130476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005;19(5):799&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2005.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4): 599&#x2013;608.</Citation></Reference><Reference><Citation>Theodoridou A, Settas L. Demyelination in rheumatic diseases. Postgrad Med J. 2008;84(989):127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.075861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo CP, Kao HW, Chen SY, Hsueh CJ, Lin WC, Hsu WL, et al. Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria. J Neurol Neurosurg Psychiatry. 2009;80(10):1107&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.169045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira S, D&#x2019;Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupup and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;44(4):434&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovaris M, Viti B, Ciboddo G, Gerevini S, Capra R, Iannucci G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry. 2000;68(2):170&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.68.2.170</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology. 2002;58(8 Suppl 4):S23-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.8_suppl_4.S23</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1032</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2000;3: CD002265.</Citation></Reference><Reference><Citation>Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2006;2:CD002265.</Citation></Reference><Reference><Citation>Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30(5):985&#x2013;92.</Citation></Reference><Reference><Citation>Harris EN, Gharavi AE, Mackworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis. 1985;44(4):281&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.44.4.281</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989;68(6):353&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-198911000-00003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990;17(1):34&#x2013;7.</Citation></Reference><Reference><Citation>Ruiz-Arguelles GJ, Guzman-Ramos J, Flores-Flores J, Garay-Martinez J. Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus. 1998;7(1):49&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120398678919633</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004;31(2):280&#x2013;5.</Citation></Reference><Reference><Citation>Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol. 2011;18(4):556&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03208.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440408</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnbaum J, Kerr D. Devic&#x2019;s syndrome in a woman with systemic lupus erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody. Arthritis Rheum. 2007;57(2):347&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22540</ArticleId></ArticleIdList></Reference><Reference><Citation>Polgar A, Rozsa C, Muller V, Matolcsi J, Poor G, Kiss EV. Devic&#x2019;s syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases. Autoimmun Rev. 2011;10(3):171&#x2013;4.</Citation></Reference><Reference><Citation>Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24937</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Moreno JM, Chacon J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord. 2002;17(6):1329&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(10):1726&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.148502</ArticleId></ArticleIdList></Reference><Reference><Citation>Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. J Rheumatol. 2008;35(11):2165&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080268</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo JF, Alonso-Juarez M, Koslowski M. Chorea in systemic lupus erythematosus. J Clin Rheumatol. 2011;17(2):69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0b013e31820e7c8d</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujieda Y, Kataoka H, Odani T, Otomo K, Kato M, Fukaya S, et al. Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Modern Rheumatol Jpn Rheum Assoc. 2011;21(3):276&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/s10165-010-0386-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnano MD, Bush TM, Herrera I, Altman RD. Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2006;35(6):396&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2006.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A, Chan BP, Yeh IB, Ho RC, Boey ML, Feng PH, et al. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology (Oxford). 2008;47(3):256&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Kim KJ, Yoon HS, Kwok SK, Ju JH, Park KS, et al. Meningitis in Korean patients with systemic lupus erythematosus: analysis of demographics, clinical features and outcomes; experience from affiliated hospitals of the Catholic University of Korea. Lupus. 2011;20(5):531&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310384495</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67(Suppl 3):iii64&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.097972</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22657</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8(2):144&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Horizon AA, Wallace DJ. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3(4):273&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.3.4.273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergent JS, Lockshin M. Azathioprine-induced meningitis in systemic lupus erythematosus. JAMA. 1978;240(6):529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.240.6.529c</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson HS, Skodol A. Special report: DSM-IV: overview and examination of major changes. Arch Psychiatr Nurs. 1994;8(6):340&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0883-9417(94)90002-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Segui J, Ramos-Casals M, Garcia-Carrasco M, de Flores T, Cervera R, Valdes M, et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus. 2000;9(8):584&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300678828730</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennekens FG, Kater L. The central nervous system in systemic lupuserythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford). 2002;41(6):605&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/41.6.605</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheikh MM, Bahakim AK, Aljabri MK, Alharthi SM, Alharthi SM, Alsaeedi AK, Alqahtani SF. Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and rituximab: an alternative to standard of care. Case Rep Rheumatol. 2022;2022:5899188. https://doi.org/10.1155/2022/5899188 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5899188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos D, Fanouriakis A, Bertsias G. Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. Expert Rev Clin Immunol. 2021;17(4):317&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1899810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Tampe B, Niebusch N, Zeisberg M, M&#xfc;ller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A, M&#xfc;ller F, Mougiakakos D, B&#xf6;ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone A, Radin M, Almarzooqi AM, Al-Saleh J, Roccatello D, Sciascia S, Khamashta M. Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2017;16(5):469&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.03.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Costenbader KH. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus. Semin Arthritis Rheum. 2022;56: 152042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lbrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Rovin BH. Expert perspective: an approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>